{"id":"xalatan-cosopt","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Conjunctival hyperemia"},{"rate":"10-30","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Increased iris pigmentation"},{"rate":"5-10","effect":"Eyelash growth"},{"rate":"5-15","effect":"Ocular surface disease"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Systemic beta-blocker effects (bradycardia, fatigue)"}]},"_chembl":{"chemblId":"CHEMBL218490","moleculeType":"Small molecule","molecularWeight":"324.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Xalatan (latanoprost) is a prostaglandin F analog that enhances uveoscleral drainage of aqueous humor. Cosopt (dorzolamide/timolol) combines dorzolamide, a topical carbonic anhydrase inhibitor that reduces aqueous humor secretion, with timolol, a non-selective beta-blocker that also decreases aqueous humor production. Together, these agents work synergistically through multiple mechanisms to lower intraocular pressure.","oneSentence":"This combination reduces intraocular pressure by combining a prostaglandin analog (latanoprost) that increases uveoscleral outflow with a carbonic anhydrase inhibitor and beta-blocker (dorzolamide/timolol) that decrease aqueous humor production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:14.509Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":"Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":36},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT00572936","phase":"PHASE2","title":"Circadian Rhythms of Aqueous Humor Dynamics in Humans","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-03-13","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT00140049","phase":"PHASE4","title":"A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":238},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT00957190","phase":"PHASE4","title":"The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)","status":"COMPLETED","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2009-05-04","conditions":"Eye Disease","enrollment":25},{"nctId":"NCT01175902","phase":"NA","title":"Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2011-03","conditions":"Normal Tension Glaucoma","enrollment":44},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00815373","phase":"NA","title":"The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)","status":"WITHDRAWN","sponsor":"Meir Medical Center","startDate":"2008-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT00804115","phase":"NA","title":"The International Collaborative Exfoliation Syndrome Treatment Study","status":"UNKNOWN","sponsor":"The New York Eye & Ear Infirmary","startDate":"2000-08","conditions":"Exfoliation Syndrome, Glaucoma, Ocular Hypertension","enrollment":277},{"nctId":"NCT00796198","phase":"PHASE4","title":"Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2008-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT00273481","phase":"PHASE4","title":"Cosopt Versus Xalacom","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":33},{"nctId":"NCT00440336","phase":"NA","title":"Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.","status":"UNKNOWN","sponsor":"Advanced Glaucoma Specialists","startDate":"2006-10","conditions":"Open Angle Glaucoma","enrollment":30},{"nctId":"NCT00273429","phase":"PHASE4","title":"Cosopt Versus Xalatan","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-04","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Xalatan+Cosopt","genericName":"Xalatan+Cosopt","companyName":"University of Turin, Italy","companyId":"university-of-turin-italy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xalatan (latanoprost 0.005%) and Cosopt (dorzolamide 2%/timolol maleate 0.5% fixed combination) are medications used to treat conditions such as open-angle glaucoma and ocular hypertension. They are small molecule drugs that work through different mechanisms, with Xalatan likely acting as a prostaglandin analog and Cosopt acting as a carbonic anhydrase inhibitor and beta-adrenergic receptor blocker.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}